Ítem
Solo Metadatos

Neuropsychiatric SLE: From animal model to human

Mostrar el registro sencillo de la publicación
dc.creatorPikman R.spa
dc.creatorKivity S.spa
dc.creatorLevy Y.spa
dc.creatorArango M.-T.spa
dc.creatorChapman J.spa
dc.creatorYonath H.spa
dc.creatorShoenfeld Y.spa
dc.creatorGofrit S.G.spa
dc.date.accessioned2020-05-25T23:56:51Z
dc.date.available2020-05-25T23:56:51Z
dc.date.created2017spa
dc.description.abstractAnimal models are a key element in disease research and treatment. In the field of neuropsychiatric lupus research, inbred, transgenic and disease-induced mice provide an opportunity to study the pathogenic routes of this multifactorial illness. In addition to achieving a better understanding of the immune mechanisms underlying the disease onset, supplementary metabolic and endocrine influences have been discovered and investigated. The ever-expanding knowledge about the pathologic events that occur at disease inception enables us to explore new drugs and therapeutic approaches further and to test them using the same animal models. Discovery of the molecular targets that constitute the pathogenic basis of the disease along with scientific advancements allow us to target these molecules with monoclonal antibodies and other specific approaches directly. This novel therapy, termed 'targeted biological medication' is a promising endeavor towards producing drugs that are more effective and less toxic. Further work to discover additional molecular targets in lupus' pathogenic mechanism and to produce drugs that neutralize their activity is needed to provide patients with safe and efficient methods of controlling and treating the disease. © The Author(s), 2016.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1177/0961203317694261
dc.identifier.issn09612033
dc.identifier.issn14770962
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22543
dc.language.isoengspa
dc.publisherSAGE Publications Ltdspa
dc.relation.citationEndPage477
dc.relation.citationIssueNo. 5
dc.relation.citationStartPage470
dc.relation.citationTitleLupus
dc.relation.citationVolumeVol. 26
dc.relation.ispartofLupus, ISSN:09612033, 14770962, Vol.26, No.5 (2017); pp. 470-477spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85018348850&doi=10.1177%2f0961203317694261&partnerID=40&md5=764293029acc41b567156cc023ac7acaspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAutoantibodyspa
dc.subject.keywordanimaleng
dc.subject.keywordBrain antigenspa
dc.subject.keywordCardiolipin antibodyspa
dc.subject.keywordComplementspa
dc.subject.keywordComplement inhibitorspa
dc.subject.keywordCrry igspa
dc.subject.keywordCyclophosphamidespa
dc.subject.keywordCytokinespa
dc.subject.keywordFisle 412 peptidespa
dc.subject.keywordHcdr1 peptidespa
dc.subject.keywordImmunoglobulinspa
dc.subject.keywordIntercellular adhesion molecule 1 antibodyspa
dc.subject.keywordN methyl dextro aspartic acid receptor antibodyspa
dc.subject.keywordN methyl dextro aspartic acid receptor nr2 antibodyspa
dc.subject.keywordP 140 peptidespa
dc.subject.keywordPeptide fragmentspa
dc.subject.keywordRibosomal p antibodyspa
dc.subject.keywordUnclassified drugspa
dc.subject.keywordVitamin dspa
dc.subject.keywordAutoantibodyspa
dc.subject.keywordCytokinespa
dc.subject.keywordApoptosisspa
dc.subject.keywordArticlespa
dc.subject.keywordBiological therapyspa
dc.subject.keywordBlood brain barrierspa
dc.subject.keywordBrain metabolismspa
dc.subject.keywordCell phagocytosisspa
dc.subject.keywordDietary supplementspa
dc.subject.keywordGenetic susceptibilityspa
dc.subject.keywordHumanspa
dc.subject.keywordImmunoregulationspa
dc.subject.keywordMental diseasespa
dc.subject.keywordMurphy roths large lymphoproliferative mousespa
dc.subject.keywordNeuroendocrine systemspa
dc.subject.keywordNeuropsychiatric systemic lupus erythematosusspa
dc.subject.keywordNonhumanspa
dc.subject.keywordNzbxnzw f1 mousespa
dc.subject.keywordPathogenesisspa
dc.subject.keywordPriority journalspa
dc.subject.keywordSystemic lupus erythematosusspa
dc.subject.keywordVaccinationspa
dc.subject.keywordAnimalspa
dc.subject.keywordBrain vasculitisspa
dc.subject.keywordDisease modelspa
dc.subject.keywordGenetic predispositionspa
dc.subject.keywordGeneticsspa
dc.subject.keywordMetabolismspa
dc.subject.keywordMousespa
dc.subject.keywordPathologyspa
dc.subject.keywordTransgenic animalspa
dc.subject.keywordAnimalsspa
dc.subject.keywordAnimalseng
dc.subject.keywordAutoantibodiesspa
dc.subject.keywordCytokinesspa
dc.subject.keywordDisease modelseng
dc.subject.keywordGenetic predisposition to diseasespa
dc.subject.keywordHumansspa
dc.subject.keywordLupus vasculitiseng
dc.subject.keywordMicespa
dc.subject.keywordAnimal modelsspa
dc.subject.keywordLupusspa
dc.subject.keywordNeuropsychiatricspa
dc.subject.keywordTargeted biological medicationspa
dc.titleNeuropsychiatric SLE: From animal model to humanspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos